We assessed the clinical outcome of pregnancies with non-Rh-D antibody in Northern Ireland using retrospective case note review. During the study period (April 1999-March 2000 186 women with clinically significant antibodies were identified from the records of the antenatal laboratory of the Northern Ireland Blood Transfusion Service. Eighty-five women were included in the study using the criteria mentioned above. None of the fetuses required intrauterine transfusion during this period. One baby required exchange transfusion, three were given top-up transfusions and 17 had phototherapy. Nine babies with a positive direct antiglobulin test (DAT) received no treatment. The incidence ofanti-Kell could be reduced by transfusing Kell negative red cells to premenopausal women. It is important that all pregnant women are tested at least twice in their pregnancy to detect the antibodies formed late in the pregnancy. It is useful to formulate a standard protocol for antenatal interventions. Non Rh-D antibodies can cause significant anaemia for up to six weeks in the neonatal period, hence early detection of maternal antibodies is important so that the neonates are followed up for an appropriate length of time.
INTRODUCTION
Although the prevalence of anti-D has significantly declined in relation to other red cell antibodies, anti-D still remains the major cause of morbidity and mortality associated with haemolytic disease of the newborn (HDN) and the fetus. The fetal and neonatal outcomes of anti-D affected pregnancies in Northern Ireland have been reported recently2. This study was undertaken to assess the management and outcome ofpregnancies in women who had other clinically significant antibodies.
METHODS
The Northern Ireland Blood Transfusion Service (NIBTS) provides centralised antibody testing for most of the antenatal clinics in the Province. Blood samples from pregnant women are tested for ABO and Rh-D group and screened for atypical antibodies. Antibody screening is performed using solid phase methodology (capture R assay) following the manufacturer's methods. The specificity of the antibody is identified by further testing ofthose samples that give positive reaction on initial screening. Table 1 . 85 women fulfilled the inclusion criteria described above ( Table 2 ). The antigen status of the partners are given in figure 1. Ten women could not be followed up for the following reasons: seven case notes were not available, one woman moved to England during pregnancy, two women were tested only once by their general practitioners and no further information was available. There was a definitive history oftransfusion in 46 (61.3%) women, and the antibody was pregnancy induced (not previously transfused) in 10 (1 3.3%) women. Transfusion history was not recorded in 19 cases, but 7 of these women had antigennegative partners, indicating that the antibody was most likely transfusion-induced. It was difficult to classify the remaining 12 women (Fig  2) . 36 (48%) women were transfused in one of their previous pregnancies following primary postpartum haemorrhage, retained placenta, ruptured ectopic pregnancy or miscarriage; two were transfused following non-obstetric surgery, two following trauma, two had transfusion to correct anaemia and the reason for transfusion was not recorded for the remaining four women. Previous obstetric history was noted in detail in women who were at risk of an affected infant i.e., women with homozygous/heterozygous partners or whose partners were not tested. 22 women had a positive antibody screen in their previous pregnancy/pregnancies and at least six of them had previously affected babies treated with phototherapy for neonatal jaundice or top-up transfusions for anaemia. Amniocentesis was possible to provide Kell negative blood to those female recipients (in the absence of anti-cellano) without depleting the blood stocks. Ninety-one percent of the population are Kell negative; 91 % of recipients will be Kell negative. NIBTS currently provides an inventory of Kell negative typed units to all hospital blood banks. The female population, aged birth to 45, is not an intensively transfused group and there will be little impact on the Kell negative inventory because ofthe balance of Kell negative to Kell positive in our population. Ideally all female recipients aged 0 to 45 should be Kell typed and this will have to be done in hospital blood banks because not all women present as antenatal cases to NIBTS for antenatal testing in the laboratory. If this recommendation is routinely implemented, the number of antiKell antibodies in pregnancies should decline slowly. However, in the case of anti-c antibodies, 50% of the women were not previously transfused in this study (Fig 2) . Hence, provision of c-antigen negative red cells to c-antigen negative recipients would be expected to make less impact on the number of cases affected with anti-c because unlike anti-Kell, most ofthe partners are c-antigen positive and induction of immunisation in pregnancy can still occur. Furthermore, this will also involve additional testing ofall Rh-D positive pregnant women for their c-antigen status. Bowell et al 10 expressed a similar opinion after a retrospective study of 177 women with anti-c over an 8-year period and concluded that routine c-antigen typing of premenopausal women was not justifiable. Kozlowski et a19 pointed out that 50% of the women with anti-c in their study had been transfused (similar to our figures) compared to 5% in unselected antenatal population. Hence they felt it was worthwhile to perform antenatal c antigen typing of all Rh D positive women and provide antigen selected blood to cover obstetric emergencies. There was no major institutional variation in the care of the neonates as there is a uniform policy among the neonatal units for the management of neonatal jaundice. All the babies were treated in NIBTS is planning to conduct a pilot study to do quantitation of anti-c to provide assistance to the obstetrician in decision-making. In a study conducted in Manchester9, none of the babies born to mothers with anti-c level below 9.5 iu/ml required exchange transfusion. Based on this observation, the authors suggested that invasive antenatal intervention is not necessary if the antic level is below 7.5 iu/ml, allowing for inherent error in quantitation method. This study highlights the fact that the clinical outcome of non Rh-D antibodies affected pregnancies is good due to careful monitoring of pregnancy and effective neonatal care. Red cell alloimmunisation remains one ofthe major causes of neonatal hyperbilirubinaemia resulting in intensive neonatal care admission. Haemolysis due to antibodies can continue to occur for up to six weeks, and the babies have to be followed up during this period to detect anaemia. It is important that laboratories undertaking antenatal testing maintain an effective working relationship and communication with the midwives, obstetricians and paediatricians to provide optimal perinatal care for the patients.
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